Gilead Sciences Target Price

Analysts' average 12-month price target for Gilead Sciences is $160.

Get informed when a big investor buys or sells

+ Follow

Share Price

$167.57

Average Target Price

$157.06

6.3% downside

16 analysts in the last 4 months

High: $195 | Low: $120

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-10-30	UBSMichael Yee	$195	16.4% upside
2026-10-30	BMO CapitalEvan David Seigerman	$184	9.8% upside
2026-10-30	Needham	$175	4.4% upside
2026-10-23	JefferiesAkash Tewari	$185	10.4% upside
2026-10-12	Raymond James	$164	2.1% downside
2026-10-08	RBC CapitalBrian Abrahams	$126	24.8% downside
2026-10-07	Truist Financial	$158	5.7% downside
2026-09-10	HSBCMorten Herholdt	$175	4.4% upside
2026-08-05	RBC Capital	$123	26.6% downside
2026-08-05	Truist Financial	$150	10.5% downside
2026-07-29	Barclays	$145	13.5% downside
2026-07-27	Morgan Stanley	$165	1.5% downside
2026-07-20	Leerink PartnersDaina Graybosch	$127	24.2% downside
2026-07-08	Morgan Stanley	$166	0.9% downside
2026-07-07	RBC CapitalBrian Abrahams	$120	28.4% downside
2026-07-06	HSBCRajesh Kumar	$155	7.5% downside
2026-06-01	RBC CapitalBrian Abrahams	$122	27.2% downside
2026-05-20	Maxim GroupMichael Okunewitch	$165	1.5% downside
2026-05-10	Morgan Stanley	$168	0.3% upside
2026-05-08	Truist Financial	$157	6.3% downside
2026-04-10	Morgan Stanley	$175	4.4% upside
2026-04-08	Truist FinancialGregory Renza	$155	7.5% downside
2026-03-10	JefferiesAkash Tewari	$180	7.4% upside
2026-02-19	Mizuho Securities	$170	1.5% upside
2026-02-19	Barclays	$155	7.5% downside
2026-02-18	UBS	$175	4.4% upside
2026-02-11	Truist Financial	$162	3.3% downside
2026-02-11	Morgan Stanley	$171	2% upside
2026-02-11	BernsteinCourtney Breen	$160	4.5% downside
2026-02-11	Truist Financial	$152	9.3% downside
2026-02-11	Cantor Fitzgerald	$155	7.5% downside
2026-02-11	Wells FargoMohit Bansal	$165	1.5% downside
2026-02-11	Oppenheimer	$165	1.5% downside
2026-02-11	Robert W. Baird	$145	13.5% downside
2026-02-11	NeedhamJoseph Stringer	$170	1.5% upside
2026-02-11	ScotiabankLouise Chen	$177	5.6% upside
2026-02-11	BMO CapitalEvan Seigerman	$160	4.5% downside
2026-01-27	Truist Financial	$145	13.5% downside
2026-01-26	UBS	$155	7.5% downside
2026-01-26	BMO CapitalEvan David Seigerman	$150	10.5% downside
2026-01-13	Morgan Stanley	$150	10.5% downside
2026-01-07	UBSMichael Yee	$145	13.5% downside
2025-12-29	BernsteinCourtney Breen	$135	19.4% downside
2025-12-15	Wolfe ResearchAlexandria Hammond	$150	10.5% downside
2025-12-12	Morgan Stanley	$151	9.9% downside
2025-12-10	HSBC	$133	20.6% downside
2025-11-25	BMO CapitalEvan David Seigerman	$135	19.4% downside
2025-11-24	Truist FinancialGregory Renza	$140	16.5% downside
2025-11-20	Mizuho Securities	$140	16.5% downside
2025-10-31	Morgan StanleyTerence Flynn	$147	12.3% downside

Gilead Sciences (GILD) FAQ

Gilead Sciences posts a target price of $160. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $160 for GILD means covering analysts, on average, see the stock 6.3% downside of $167.57 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for GILD's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Gilead Sciences's other metric pages and overview cover the third.

Judging Gilead Sciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $160 here, then scan peer and history charts to see if the gap is persistent.